FBLG

FibroBiologics, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001958777 Biotech & Drug Discovery

$0.9024 −0.05 (−5.01%)

Oct 26 4:00 PM ET · prev $0.9500

Market cap

$6.9M

Nano cap

Consensus

Buy

86% Buy or better · 7 analysts

Median target

$12.50

+1285% · range $6.00–19.00

Next earnings

Nov 17

in 22 days · EPS est. −$0.63

1 year

−89.6%

from $8.66 · Oct 27

30 days

−33.6%

from $1.36

52-week range

$0.6270–8.70

−90% from high · low Jul 27

Avg volume 20D

147.8K

Oct 22 spike 398.5K

Short interest

522.1K

≈7.8% of shares · −21.1%

Days to cover

3.8

at average volume

Insider net

+$73.0K

4 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

SecBot read BEARISH 6 reports · 90 days

Balance 3 bearish · 0 bullish · 3 neutral oldest → newest, height = score

Avg score

·High conf. 4/6 ·Next Earnings date, Nov 17, 2026

Strongest BEARISH FibroBiologics issued a $1.2M convertible debenture to Peak One Opportunity Fund at a 15% original issue…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Feb 27 to Mar 4 4 days of insider buys: $73.0K by 4 insiders, avg $0.3810
A May 4 Maxim Group downgrades
E May 11 FDA: FibroBiologics Advancing Development of a Fibroblast Treat…
R Jul 17 The SEC declared effective FibroBiologics' S-1 registration statemen…
X Jul 31 Short interest jumps 62.6% to 115.2K
X Aug 31 Short interest jumps 192.0% to 413.7K
X Sep 15 Short interest jumps 60.0% to 661.9K
R Oct 8 FibroBiologics issued a $1.2M convertible debenture to Peak One Oppo…

Signal stack

Where each data set points today.

InsidersBULLISH

4 insiders bought $73.0K. No open-market sales.
InstitutionsMIXED

Q2 2026: 2 added (0 new), 3 trimmed or exited.
AnalystsBULLISH

6 of 7 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.770 → −$0.630 over 90 days. 1 up, 0 down in 30 days.
Short sellersCOVERING

Short interest −21.1% to 522.1K shares. 3.8 days to cover, ≈7.8% of shares.
TrendDOWNTREND

32% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	TRIM	27,769	$26.3K
BlackRock, Inc.	TRIM	18,238	$17.3K
OSAIC HOLDINGS, INC.	DOUBLED	2,404	$2.3K
UBS Group AG	NEAR_EXIT	1,073	$1.0K
ROYAL BANK OF CANADA	DOUBLED	1,522	$1.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts

Buy 86% rate it Buy or better

Strong Buy2Buy4Hold1Sell0Strong Sell0

12-month targets · 2 analysts

$0.9024 $6.00 $12.50 $19.00

Price is below the lowest target. Median implies +1285%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 4, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
May 4, 2026	Maxim Group DOWNGRADE	DOWNGRADE	Hold

Insider ledger

Form 4

$73.0K

bought · 4 insiders

sold · 0 insiders

Date	Insider	Type	Value
Sep 15, 2026	Khoja Hamid Chief Scientific Officer	AWARD	$500.0K
Sep 15, 2026	Khoja Hamid Chief Scientific Officer	AWARD	298,508 sh
Jun 23, 2026	Niklas Victoria Ninon Olivia Director	AWARD	30,803 sh
Jun 23, 2026	Hoffman Robert E. Director	AWARD	30,803 sh
Jun 23, 2026	Link Matthew Director	AWARD	30,803 sh
Jun 23, 2026	Cilento Richard C. Jr. Director	AWARD	30,803 sh
May 4, 2026	GARCIA RUBEN A General Counsel	AWARD	61,607 sh
May 4, 2026	Davis Jason Chief Financial Officer	AWARD	61,607 sh

Earnings setup

Estimates

Nov 17

reports in 22 days

−$0.63

EPS estimate, this quarter

+18%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.770

90d

−$0.940

60d

−$0.940

30d

−$0.940

−$0.630

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.63	-$0.63–-$0.63	+33.0%	$0.00
Next Q	-$0.63	-$0.63–-$0.63	+33.0%	$0.00
Current FY	-$3.00	-$3.00–-$3.00	+25.2%	$0.00
Next FY	-$3.25	-$3.25–-$3.25	+27.6%	$0.00